How Much Weight Can You Lose on Wegovy? Insights and Expectations

Last reviewed: June 17, 2026

Last updated: June 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Wegovy, has demonstrated significant weight loss potential in clinical trials, with patients losing an average of 15–22% of their starting body weight. However, individual results depend on genetic factors, adherence to lifestyle changes, and personalized dosing. PlexusDx provides access to compounded semaglutide from licensed 503A pharmacies, allowing patients to pursue this therapy without insurance barriers.

Average Weight Loss on Semaglutide: What Clinical Trials Show

The STEP trials, which evaluated semaglutide for weight management, documented weight reductions ranging from 15–22% of body weight compared to placebo, which produced only 2–3% loss. Patients receiving the highest maintenance dose (2.4 mg weekly) achieved greater reductions than those on lower doses. These results were sustained over 68 weeks of treatment, demonstrating that semaglutide's effect on appetite and blood sugar regulation provides lasting metabolic benefits.

Individual weight loss varies significantly based on several factors: starting body weight, baseline metabolism, concurrent health conditions, diet quality, and physical activity level. A patient beginning treatment at 250 pounds might expect to lose 37–55 pounds over one year, while outcomes depend heavily on consistency with medication and lifestyle modifications. Genetic predispositions also influence how effectively someone's body responds to GLP-1 pathway activation.

Timeline: When Weight Loss Begins on Semaglutide Injections

Most patients notice reduced appetite and initial weight changes within the first 2–4 weeks of starting semaglutide, though the scale may not shift dramatically until week 4–8. The medication works by slowing gastric emptying and signaling satiety to the brain, which allows people to feel full on smaller portions naturally. Weight loss typically accelerates as doses increase during the titration phase, which usually spans 16–20 weeks.

After the maintenance dose is reached (usually 2.4 mg weekly for most patients), weight loss continues gradually over subsequent months. Plateau periods are common and do not indicate treatment failure—they reflect the body's new metabolic set point. Sustained weight loss typically continues through month 12, with many patients experiencing the majority of their total loss by month 6–9 of consistent use.

Factors That Influence Your Individual Weight Loss Results

Genetic variation in appetite-regulating pathways directly affects how your body responds to semaglutide. The GLP1R rs6923761 variant, MC4R rs17782313, and GIPR rs1800437 polymorphisms influence baseline sensitivity to GLP-1 agonists. PlexusDx's Precision Peptide Genetic Test maps these pathways alongside 14 additional metabolic routes, revealing which peptide-based therapies align best with your unique genetic architecture—enabling truly personalized dosing strategies.

Lifestyle consistency ranks equally with genetics: patients who maintain structured eating patterns, prioritize protein intake, and engage in regular physical activity achieve significantly better outcomes than those relying on medication alone. Underlying conditions like polycystic ovary syndrome (PCOS), type 2 diabetes, and thyroid dysfunction can modulate weight loss velocity. Sleep quality, stress management, and medication adherence also predict long-term success.

Semaglutide vs. Wegovy: Cost, Access, and PlexusDx Options

Wegovy, the brand-name injectable semaglutide for weight management, often costs $900–$1,500 monthly without insurance, making it inaccessible for many patients. PlexusDx compounded semaglutide injections start at $149 per month from licensed 503A compounding pharmacies, delivering the same active pharmaceutical ingredient at a fraction of the cost. No membership fees, no insurance requirement, and HSA/FSA eligibility remove financial barriers to treatment.

Compounded medications from 503A pharmacies undergo rigorous quality oversight and potency testing, ensuring bioequivalence to brand formulations. PlexusDx serves all 50 states and offers optional Precision Peptide Genetic Testing ($99 add-on after the first month) to inform personalized dosing and identify which GLP-1 or GLP-1/GIP dual-agonist formulation aligns with your genetic predispositions. Your dose may need to go up. Your price won't.

Sustaining Weight Loss: Maintenance and Long-Term Expectations

Weight loss on semaglutide is not temporary if the medication is continued; studies show that weight regains occur primarily in patients who discontinue therapy. The appetite-suppressing and metabolic effects persist as long as the medication remains in your system at therapeutic doses. Most healthcare providers recommend ongoing maintenance therapy rather than time-limited treatment, as the underlying genetic and metabolic drivers of excess weight remain unchanged after stopping.

Plateaus do not mean treatment has failed—they indicate your body has adapted to the lower weight and new caloric intake. Minor dose adjustments, increased physical activity, or dietary refinement can help overcome plateaus without abandoning therapy. Long-term adherence to semaglutide, combined with sustained lifestyle habits, produces durable weight loss outcomes that significantly reduce cardiometabolic disease risk, regardless of initial starting weight or age.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will I lose weight immediately after starting semaglutide?

Initial appetite suppression begins within days, but measurable weight loss typically appears in weeks 2–4. Most patients see accelerating loss once they reach higher maintenance doses around week 8–12. Patience during the titration phase is crucial, as the body adjusts to the medication's effects.

What percentage of body weight do most Wegovy users lose?

Clinical trials show average losses of 15–22% of starting body weight over 68 weeks, with higher doses producing greater reductions. A patient weighing 220 pounds might realistically lose 33–48 pounds, though individual results depend on genetics, diet, activity, and adherence. PlexusDx's genetic testing can help predict your likely response trajectory.

How much cheaper is PlexusDx semaglutide compared to brand Wegovy?

PlexusDx compounded semaglutide injections start at $149 per month, compared to $900–$1,500 monthly for Wegovy without insurance. That represents 80–85% savings while delivering identical active pharmaceutical ingredient from licensed 503A compounding pharmacies. No insurance needed, and HSA/FSA funds are accepted.

Will my weight come back if I stop taking semaglutide?

Weight regain typically occurs within 12 months of stopping semaglutide, as appetite-suppressing and metabolic effects diminish. However, many patients maintain 50–75% of their loss if they sustain the lifestyle habits adopted during treatment. Long-term therapy is recommended by most experts to preserve benefits and prevent disease recurrence.

How does the Precision Peptide Genetic Test help predict my weight loss?

PlexusDx's genetic test identifies variants in GLP1R, GIPR, MC4R, FTO, and 45+ additional peptide-pathway genes that influence appetite regulation, metabolic rate, and GLP-1 drug sensitivity. Patients with favorable variants in GLP1R rs6923761 often experience faster, greater weight loss at lower doses, enabling truly personalized, efficient dosing strategies—not one-size-fits-all treatment.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Wegovy For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.